Variceal bleeding is the most serious complication of portal hypertension. All cirrhotic patients should be screened endoscopically for varices which are present in about 30% of compensated and 60% of decompensated patients at diagnosis. In patients without varices, endoscopy surveillance should be continued every 2 years. Patients with high-risk varices (moderate or large in size, or with red color signs, or in Child-Pugh C patients) should be treated with a nonselective β-blocker to prevent bleeding (propranolol, nadolol or carvedilol). Endoscopic banding ligation is also effective for the prevention of first bleeding, and it is the first choice in patients with contraindications or intolerance to β-blockers. Acute variceal hemorrhage still has a high mortality rate (around 15%) and requires intensive care management and conservative blood transfusion policy. Treatment is based on the combined use of vasoactive drugs, endoscopic band ligation and prophylactic antibiotics. Failures are best managed by transjugular intrahepatic portosystemic shunt (TIPS). Balloon tamponade or specifically designed covered esophageal stents can be used as a bridge to definitive therapy in unstable patients. Early, preemptive TIPS might be the first choice in patients at high risk of failure (Child-Pugh B with active bleeding or Child-Pugh C up to 13 points). Patients surviving a variceal bleeding are at high risk of rebleeding. A combination of β-blockers and endoscopic band ligation is the most effective therapeutic approach. Preliminary data suggest that the addition of simvastatin increases survival in these patients.

1.
Sikuler E, Groszmann RJ: Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986;250:G205-G212.
2.
Groszmann RJ, Abraldes JG: Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005;39:S125-S130.
3.
Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC: Portal hypertension and gastrointestinal bleeding. Semin Liver Dis 2008;28:3-25.
4.
Vorobioff J, Bredfeldt JE, Groszmann RJ: Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G57.
5.
Bosch J, Abraldes JG, Groszmann RJ: Current management of portal hypertension. J Hepatol 2003;38:S54-S68.
6.
de Franchis R: Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-768.
7.
Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al: Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-2261.
8.
North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices: Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983-989.
9.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W: Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-938.
10.
Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, et al: Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-709.
11.
Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH: Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013;19:6849-6856.
12.
Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, et al: Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis: a 12-year prospective follow-up study. Hepatology 2010;51:2069-2076.
13.
Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, et al: Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011;54:555-561.
14.
Muting D, Kalk JF, Fischer R, Wiewel D: Spontaneous regression of oesophageal varices after long-term conservative treatment: retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis. J Hepatol 1990;10:158-162.
15.
Fracanzani AL, Fargion S, Romano R, Conte D, Piperno A, D'Alba R, Mandelli C, et al: Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995;22:1127-1131.
16.
Cales P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, et al: Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol 1999;11:741-745.
17.
Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, et al: A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-484.
18.
D'Amico G, Pagliaro L, Bosch J: Pharmacological treatment of portal hypertension: an evidence-based approach. Sem Liv Dis 1999;19:475-505.
19.
Chen W, Nikolova D, Frederiksen SL, Gluud C: Beta-blockers reduce mortality in cirrhotic patients with oesophageal varices who have never bled (Cochrane review; abstract). J Hepatol 2004;40(suppl 1):67.
20.
Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, et al: Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-1022.
21.
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, et al: Non-selective β-blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014;146:1680-1690.
22.
Leithead JA, Rajoriya N, Tehami N, Hodson J, Gunson BK, Tripathi D, Ferguson JW: Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut 2014, Epub ahead of print.
23.
Bosch J: Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 2010;51:2214-2218.
24.
Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, et al: Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825-833.
25.
Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, et al: Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013;62:1634-1641.
26.
Angelico M, Carli L, Piat C, Gentile S, Rinaldi V, Bologna E, Capocaccia L: Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis. Gastroenterology 1993;104:1460-1465.
27.
Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, Genesca J, et al: Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-1266.
28.
D'Amico G, Pasta L, Politi F, Vizzini G, Traina M, Caltagirone M, Patti R, et al: Isosorbide mononitrate with nadolol compared to nadolol alone for prevention of the first bleeding in cirrhosis: a double-blind placebo-controlled randomized trial. Gastroenterol Int 2002;15:40-50.
29.
Gluud LL, Klingenberg S, Nikolova D, Gluud C: Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007;102:2842-2848.
30.
Gluud LL, Krag A: Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012;8:CD004544.
31.
Garcia-Pagan JC, De Gottardi A, Bosch J: Review article: the modern management of portal hypertension - primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008;28:178-186.
32.
Hernandez-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Minana J, et al: Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol 2012;107:418-427.
33.
Northup PG, Henry ZH: Editorial: Beta-blockers and the prevention of decompensation in cirrhosis: worth the trouble. Am J Gastroenterol 2012;107:428-430.
34.
Longacre AV, Imaeda A, Garcia-Tsao G, Fraenkel L: A pilot project examining the predicted preferences of patients and physicians in the primary prophylaxis of variceal hemorrhage. Hepatology 2008;47:169-176.
35.
Bosch J, Garcia-Pagan JC: Prevention of variceal rebleeding. Lancet 2003;361:952-954.
36.
Garcia-Tsao G: Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 2007;46:499-507.
37.
Thiele M, Krag A, Rohde U, Gluud LL: Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012;35:1155-1165.
38.
Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, et al: Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to β-blocker alone. Hepatology 1997;26:34-39.
39.
Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP: Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-1245.
40.
Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, Keough A, et al: A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014;146:412-419.
41.
Mayorga CA, Rockey DC: Clinical utility of a standardized electronic order set for the management of acute upper gastrointestinal hemorrhage in patients with cirrhosis. Clin Gastroenterol Hepatol 2013;11:1342-1348.
42.
Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, et al: Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
43.
Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez AJ, Fabricius S, et al: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004;127:1123-1130.
44.
Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, et al: Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008;47:1604-1614.
45.
Bendtsen F, D'Amico G, Rusch E, de Franchis R, Andersen PK, Lebrec D, Thabut D, et al: Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol 2014;61:252-259.
46.
Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M: Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;9:CD002907.
47.
Fernandez J, Ruiz dA, Gomez C, Durandez R, Serradilla R, Guarner C, Planas R, et al: Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-1056.
48.
Banares R, Albillos A, Rincon D, Alonso S, Gonzalez M, Ruiz-del-Arbol L, Salcedo M, et al: Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609-615.
49.
Wells M, Chande N, Adams P, Beaton M, Levstik M, Boyce E, Mrkobrada M: Meta-analysis: vasoactive medications for the management of acute variceal bleeds. Aliment Pharmacol Ther 2012;35:1267-1278.
50.
Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, Jang BK, et al: Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60:954-963.
51.
Villanueva C, Piqueras M, Aracil C, Gomez C, Lopez-Balaguer JM, Gonzalez B, Gallego A, et al: A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006;45:560-567.
52.
Avgerinos A, Armonis A, Stefanidis G, Mathou N, Vlachogiannakos J, Kougioumtzian A, Triantos C, et al: Sustained rise of portal pressure after sclerotherapy, but not band ligation, in acute variceal bleeding in cirrhosis. Hepatology 2004;39:1623-1630.
53.
Hubmann R, Bodlaj G, Czompo M, Benko L, Pichler P, Al Kathib S, Kiblbock P, et al: The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy 2006;38:896-901.
54.
Wright G, Lewis H, Hogan B, Burroughs A, Patch D, O'Beirne J: A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center. Gastrointest Endosc 2010;71:71-78.
55.
Bosch J: Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving? J Hepatol 2001;35:658-660.
56.
Escorsell A, Bandi JC, Andreu V, Moitinho E, Garcia-Pagan JC, Bosch J, Rodes J: Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-169.
57.
Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, Marrero JM, et al: Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793-801.
58.
Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, et al: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-2379.
59.
Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, Luca A, et al: Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013;58:45-50.
60.
Rudler M, Cluzel P, Corvec TL, Benosman H, Rousseau G, Poynard T, Thabut D: Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding, without improving survival. Aliment Pharmacol Ther 2014;40:1074-1080.
61.
Lui HF, Stanley AJ, Forrest EH, et al: Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-744.
62.
Lo GH, Chen WC, Chen MH, et al: Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-338.
63.
Schepke M, Kleber G, Nurnberg D, et al: Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72.
64.
Lay CS, Tsai YT, Lee FY, et al: Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006;21:413-419.
65.
De BK, Ghoshal UC, Das T, Santra A, Biswas PK: Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomized controlled trial. J Gastroenterol Hepatol 1999;14:220-224.
66.
Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS: Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding [see comments]. N Engl J Med 1999;340:988-993.
67.
Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J: Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128:870-881.
68.
Psilopoulos D, Galanis P, Goulas S, et al: Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005;17(10):1111-1117.
69.
Thuluvath PJ, Maheshwari A, Jagannath S, Arepally A: A randomized controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci 2005;50:407-410.
70.
Norberto L, Polese L, Cillo U, et al: A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl 2007;13:1262.
71.
Perez-Ayuso RM, Valderrama S, Espinoza M, et al: Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol 2010;9:15-22.
72.
Chen CY, Sheu MZ, Su SY: Prophylactic endoscopic variceal ligation for esophageal varices. Gastroenterology 1998;114:1224A.
73.
Song H, Shin JW, Kim HI, et al: A prospective randomized trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high risk esophageal varices. J Hepatology 2000;32(suppl 2):41A.
74.
de la M, Farca-Belsaguy AA, Uribe M, de Hoyos-Garza A: Ligation vs propranolol for primary prophylaxis of variceal bleeding using multiple band ligator and objective measurements of treatment adequacy: preliminary results. Gastroenterology 2000;118:6511A.
75.
Drastich P, Lata J, Petrtyl J, et al: Endoscopic variceal band ligation in comparison with propranolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis. J Hepatol 2005;42:202A.
76.
Abdelfattah MH, Rashed MA, Elfakhry AA, Soliman MA, Shiha GH: Endoscopic variceal ligation versus pharmacological treatment for primary prophylaxis of variceal bleeding: a randomized study. J Hepatol 2006;44(suppl 2):83A.
77.
Gheorghe C, Gheorghe L, Iacob S, Iacob R, Popescu I: Primary prophylaxis of variceal bleeding in cirrhotics awaiting liver transplantation. Hepatogastroenterology 2006;53:552-557.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.